{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:01:10Z","timestamp":1773770470120,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T00:00:00Z","timestamp":1488844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.urolonc.2017.03.009","type":"journal-article","created":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T20:24:37Z","timestamp":1491251077000},"page":"529.e9-529.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer\u2014GEnetic- and tumor-related biomarkers for response and toxicity"],"prefix":"10.1016","volume":"35","author":[{"given":"Loes F.M.","family":"van der Zanden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sita H.","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arna","family":"Oskarsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake S.F.","family":"Maurits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meta H.M.","family":"Diekstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Ambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Cambon-Thomsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Garcia Donas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Guarch Troyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Hulsbergen-van de Kaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Jaehde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Junker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Martinez-Cardus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisli","family":"Masson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannette","family":"Oosterwijk-Wakka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius T.","family":"Radu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorunn","family":"Rafnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Rodriguez-Antona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Ruijtenbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Stefansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lodewyk","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambertus A.L.M.","family":"Kiemeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egbert","family":"Oosterwijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2017.03.009_bib1","series-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]","author":"Ferlay","year":"2013"},{"key":"10.1016\/j.urolonc.2017.03.009_bib2","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.ejca.2008.04.014","article-title":"No improvement in renal cell carcinoma survival: a population-based study in the Netherlands","volume":"44","author":"Aben","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2017.03.009_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2007.12.001","article-title":"Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review","volume":"34","author":"Gupta","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2017.03.009_bib4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00345-016-1773-y","article-title":"Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study","volume":"34","author":"Dabestani","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2017.03.009_bib5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/ki.2013.245","article-title":"Renal cell carcinoma: translational aspects of metabolism and therapeutic consequences","volume":"84","author":"Yang","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.urolonc.2017.03.009_bib6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2017.03.009_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2017.03.009_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14020","article-title":"Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation","volume":"14","author":"Thompson Coon","year":"2010","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.urolonc.2017.03.009_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40425-016-0180-7","article-title":"Society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma","volume":"4","author":"Rini","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2017.03.009_bib10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","article-title":"EAU guidelines on renal cell carcinoma: 2014 update","volume":"67","author":"Ljungberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.03.009_bib11","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.03.009_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.03.009_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2017.03.009_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2016.10.007","article-title":"Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma","volume":"71","author":"Hsieh","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.03.009_bib15","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-09-3965","article-title":"Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma","volume":"70","author":"Huang","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2017.03.009_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-5-32","article-title":"Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins","volume":"5","author":"Deprimo","year":"2007","journal-title":"J Transl Med"},{"key":"10.1016\/j.urolonc.2017.03.009_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/tpj.2015.100","article-title":"Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma","volume":"17","author":"Diekstra","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.urolonc.2017.03.009_bib18","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1158\/1078-0432.CCR-13-1351","article-title":"Molecular biomarkers in advanced renal cell carcinoma","volume":"20","author":"Maroto","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2017.03.009_bib19","first-page":"1","article-title":"Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives","volume":"1855","author":"Joosten","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.urolonc.2017.03.009_bib20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12885-016-2395-x","article-title":"Variation in use of targeted therapies for metastatic renal cell carcinoma: results from a Dutch population-based registry","volume":"16","author":"De Groot","year":"2016","journal-title":"BMC Cancer."},{"key":"10.1016\/j.urolonc.2017.03.009_bib21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1470-2045(11)70266-2","article-title":"Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study","volume":"12","author":"Garcia-Donas","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2017.03.009_bib22","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.2008.21.7679","article-title":"Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity","volume":"27","author":"van Erp","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.03.009_bib23","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1038\/ncomms3776","article-title":"A common variant at 8q24.21 is associated with renal cell cancer","volume":"4","author":"Gudmundsson","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2017.03.009_bib24","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43-9.","DOI":"10.1038\/nature12222"},{"key":"10.1016\/j.urolonc.2017.03.009_bib25","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.celrep.2016.02.024","article-title":"Multilevel genomics-based taxonomy of renal cell carcinoma","volume":"14","author":"Chen","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.urolonc.2017.03.009_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/469156a","article-title":"Bring on the biomarkers","volume":"469","author":"Poste","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2017.03.009_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.urology.2016.04.042","article-title":"Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: results from a population-based registry","volume":"95","author":"de Groot","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.03.009_bib28","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2017.03.009_bib29","doi-asserted-by":"crossref","first-page":"e0148177","DOI":"10.1371\/journal.pone.0148177","article-title":"Association study of a functional variant on ABCG2 gene with sunitinib-induced severe adverse drug reaction","volume":"11","author":"Low","year":"2016","journal-title":"PLoS One."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917301096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917301096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:11:23Z","timestamp":1761041483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143917301096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1078143917301096"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.03.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer\u2014GEnetic- and tumor-related biomarkers for response and toxicity","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}